FDA Approves Skin Cancer Drug
Posted on: Friday, 13 October 2006, 09:02 CDT
The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.
The FDA approved Zolinza capsules for the treatment of cutaneous T-cell lymphomalymphoma, a lymphoma that affects the skin. The FDA, in a news release, said the drug was approved to use when the disease worsens, is persistent or returns after treatment with other drugs.
About 3 in 1 million people, mainly middle-aged men, are diagnosed with CTCL each year, the FDA said.
The FDA said it approved Zolinza as part of its Orphan Drug program, which offers companies financial incentives to develop medicines for diseases and conditions affecting fewer than 200,000 people in the United States a year.
Zolinza is manufactured by Pantheon Inc. for Merck & Co. Inc., the FDA said.
Source: United Press International
Related Articles
- European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
- Crystallize Your Business Decisions With Drug Approval Trends at the FDA and EMEA Report
- GAO to Enquire into FDA's Drug Approval Policies
- Sagient Research Reports Significant Decline in FDA Drug Approval Rate
- Almost All New Drug Approvals Receive FDA Requests for Post-Marketing Studies
- Synovics Gets First FDA Generic Approval
- FDA Lifts Approvals Hold on Pliva Facilities
- PROFNET WIRE: HEALTH & MEDICINE: FDA Drug Approval
- FDA Drug Approval Times Likely to Grow
- FDA Grants Approval for New Oral Solution of LEVAQUIN(R)
 |
 |
User Comments (0)
RSS Feeds